A t(4;11)(q21;q23) has been described in 50-70% of cases of infant acute lymphoblastic leukemia and, less frequently, in cases of pediatric and adult acute lymphoblastic leukemia and acute myeloid leukemia (AML). In t(4;11)(q21;q23) leukemias, the AF4 gene has been cloned as a fusion partner of the MLL gene. A human myeloid leukemia cell line, chronic neutrophilic leukemia (CNL)BC1, was established from a peripheral blood specimen of a patient with CNL in leukemic transformation. As with the original leukemia cells, the established line had a t(4;11)(q21;q23). We showed that the MLL gene on 11q23 was fused to the FLJ10849 gene on 4q21. The protein encoded by FLJ10849 belongs to the septin family, sharing highest homology with human SEPT6, which is one of the fusion partners of MLL in t(X;11)(q13;q23) AML. Our results suggest that FLJ10849 might define a new septin family particularly involved in the pathogenesis of 11q23-associated leukemia. The established cell line, CNLBC1, could provide a useful model for analyzing the pathogenesis of MLL-septin leukemias and chronic neutrophilic leukemia.
Introduction
Chronic neutrophilic leukemia (CNL) is a rare disorder characterized by a sustained increase of mature neutrophils in the blood, myeloid hyperplasia in the bone marrow (BM), absence of the Philadelphia (Ph) chromosome and frequent transformation to acute myeloid leukemia (AML). 1, 2 Fewer than 100 cases of CNL have been reported since its original description in 1920, with inconsistent cytogenetic abnormalities. [1] [2] [3] The etiology of CNL is currently unknown. MLL (ALL1, Htrx, HRX), which is located on chromosome 11 band q23, is frequently rearranged by chromosome translocations in acute leukemias. 4, 5 At present, there are more than 60 partner genes for MLL. 4 Although the functions of the fusion transcripts remain largely unknown, it is thought for several reasons that the partner gene is critical for leukemogenesis. [6] [7] [8] First, all previously reported partner genes are fused in-frame to MLL, resulting in a novel fusion protein rather than simply a truncation of MLL. Second, in a knockin model system, only mice with a fusion partner identical to that seen in human leukemia developed leukemias, suggesting that the fusion product is critical for leukemogenesis. Furthermore, in a murine BM immortalization system, the ENL partner gene was critical for immortalization and leukemogenesis. Some of the partner genes are related to each other, such as AF9/ENL, AF10/AF17, AFX/AF6q21 and CBP/p300. [9] [10] [11] [12] [13] [14] [15] Septins are a family of cytoskeletal proteins with GTPase activity, assembling as intracellular filamentous scaffolds putatively involved in cytokinesis, cellular morphogenesis, neuronal polarity, vesicle trafficking and apoptosis. [16] [17] [18] In humans, 10 septin genes have been documented, including SEPT1, SEPT2 (Nedd5, Diff6, PNUTL3), SEPT3, SEPT4 (PNUTL2, Bradeion), SEPT5 (PNUTL1, hCDCrel16), SEPT6 (Septin6, KIAA0128), SEPT7 (hCDC10), SEPT8 (KIAA0202), SEPT9 (MSF, AF17q25, PNUTL4) and SEPT10. [18] [19] [20] [21] [22] [23] [24] [25] All human septins contain an evolutionarily conserved GTPase motif near the N-terminus, and generally possess a coiled-coil domain at the C-terminus. Among them, the three septins SEPT5, 20,21 SEPT6, 22, 23 and SEPT9 24, 25 have previously been reported to be among the targets for MLL fusions. They are fused in-frame to MLL, resulting in novel fusion proteins. t(4;11)(q21;q23) is a recurring chromosomal translocation observed in acute leukemias, and AF4 (MLLT2) on chromosome 4q21 has previously been cloned as a fusion partner of MLL. [26] [27] In this study, we identified the FLJ10849 gene as a novel fusion partner of the MLL gene in a human myeloid leukemia cell line established from CNL in blastic transformation with t(4;11)(q21;q23).
Materials and methods

Patient
A 63-year-old woman was referred to us because of leukocytosis. Physical examination revealed mild hepatosplenomegaly. Her hemoglobin concentration was 10.4 g/dl, white blood cell count 121 Â 10 9 /l with 3% metamyelocytes, 92% neutrophils, 1% basophils, 1% eosinophils, 2% monocytes and 1% lymphocytes and platelet count 67 Â 10 9 /l. There were few circulating myeloblasts. Neutrophil alkaline phosphatase activity was increased (rate 100%, score 361). The vitamin B12 serum level was elevated to 4 440 pg/ml (normal, 240-840 pg/ml). The serum level of granulocyte-colony-stimulating factor was reduced to o5 pg/ml (normal, 8-20 pg/ml). Immunoelectrophoresis did not demonstrate serum paraprotein. A BM film revealed markedly hypercellular marrow with 94% myeloid cells at various stages of maturation and a normal proportion of blasts. Myelodysplastic features were not detected. Chromosomal analysis showed 49, XX, þ X, þ 8, þ 21 in all 20 metaphases. There was no Ph chromosome and no rearrangement of the major BCR upon Southern blotting. Reverse-transcriptase polymerase chain reaction (RT-PCR) amplification did not yield BCR/ABL fusion transcripts. A diagnosis of CNL was made. She was treated with hydroxyurea, which brought about a partial hematologic response. A leukemic transformation occurred 8 months after diagnosis (Figure 1a ). Leukemic cells expressed CD13, CD33 and CD34, and were cytogenetically characterized as 49, XX, þ X, þ 8, þ 21, t(4;11)(q21;q23) in 19 of 20 metaphases analyzed. She died of refractory leukemia 16 months after initial diagnosis.
Cell line establishment
At the blastic crisis, a heparinized peripheral blood specimen was obtained with informed consent. Mononuclear cells were isolated by Ficoll-Hypaque density-gradient centrifugation. The interface containing mononuclear cells was harvested and washed twice with fresh RPMI 1640 culture medium. Mononuclear cells were suspended in RPMI 1640 medium supplemented with 10% heat-inactivated FCS without additional growth factors; cells were incubated in a plastic culture flask (Sumitomo, Tokyo, Japan) at 371C in a humidified 5% CO 2 atmosphere. During the subsequent 2 weeks, the culture was fed once or twice a week by replacing one-half to one-third of the volume of the culture with fresh nutrient medium. In the third week, a slow yet sustained proliferation of the cultured cells was noted. In April 2002, the cell line was designated as CNLBC1.
PCR, as described previously, showed the cell line to be free of Epstein-Barr virus infection or mycoplasma infection.
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Morphological studies
Microscopic observation was performed on cytospin smears of the established cell line after May-Grü nwald-Giemsa staining. Cytochemical staining for myeloperoxidase was also performed using cytospin smears and standard methodology.
Immunophenotyping
Immunophenotyping of fresh leukemic blasts and of the cell line was performed with the antibodies listed in Table 1 . The sources of these reagents and the methods used have been described in detail elsewhere.
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Cytogenetic analysis
Cytogenetic analysis was carried out on trypsin G-banded chromosome preparations, and karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN) 1995. Table 1 Immunomarker profiles of established CNLBC1 cells and primary leukemia blasts 
Southern blot analysis
High molecular weight DNA was extracted from cell line cells by proteinase K digestion and phenol/chloroform extraction. DNA (5 mg) was digested with appropriate restriction enzymes, subjected to electrophoresis on 0.7% agarose gels, transferred to charged nylon filters (Amersham Biosciences Corp., Piscataway, NJ, USA), and hybridized with a cDNA probe labeled by the random hexamer method. A 0.74-kb BamHI fragment derived from MLL cDNA, which contains exons 8-14 encompassing the breakpoint cluster region, was used as a probe. 30 There are two numbering systems of MLL exons; the most recent system will be used in this report. 31 
RNA extraction
Total RNAs were extracted from BM cells at diagnosis, BM cells at blast crisis, and cell line cells with the RNeasy Mini Kit (Qiagen, Hilden, Germany).
cDNA panhandle PCR
Total RNA extracted from cell line cells was analyzed by a modified cDNA panhandle PCR method as described previously. 32 
Nucleotide sequencing
The PCR products were cloned into the TA cloning vector (Invitrogen, San Diego, CA, USA). Plasmids were sequenced by use of the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and an automated sequencer (model 310, Applied Biosystems). Searches for sequence similarity were performed with the GeneBank nucleic acid and protein databases by using the BLAST program.
RT-PCR
RT-PCR was carried out for the detection of MLL-FLJ10849 and reciprocal FLJ10849-MLL chimeric transcripts. The primers used were the following: MLL-3974F (nucleotides 3974-3993, GenBank accession no. NM_005933), 5 0 -GTGAGCCCAA-GAAAAAGCAG-3'; SEPT-304R (322-304, NM_018243), 0 -CATTGGAGAGAGTGCTGAGG-3'. First-strand cDNA synthesis was performed with oligo(dT) as primer (Superscript III System, Invitrogen). The cDNA template (1((l) was amplified in a 50-ml PCR mix (TaKaRa, Otsu, Japan) containing 1 Â reaction buffer, 0.2 mmol/l dNTPs, 0.5 mmol/l forward and reverse primers (MLL-3974F and SEPT-304R for the MLL-FLJ10849 transcript, and SEPT-89F and MLL-4240R for the FLJ10849-MLL transcript) and 1 U Taq DNA polymerase. The PCR procedure consisted of 30 repetitive, three-step cycles, with 1 min each of incubation at 96, 55, and 721C, respectively. A nested PCR was performed for the detection of the FLJ10849-MLL transcript, and the reamplification for 30 cycles of a 0.5 ml aliquot of the first reaction was performed using internal SEPT-111F and MLL-4137R primers. Synthesis of cDNA was controlled by amplifying b-actin. The PCR product was electrophoresed on an ethidium bromide-stained 1% agarose gel and observed under UV light.
To investigate whether alternatively spliced FLJ10849 mRNA could be expressed in the MLL-FLJ10849 transcripts, we also performed RT-PCR using a sense primer MLL-4048F (4048- 
XL-PCR
For the detection of genomic MLL-FLJ10849 hybrid, extralong (XL)-PCR was performed in 50 ml of 1x reaction buffer, 0.4 mM. of each dNTP, 2.5 mmol MgCl 2 , 2.5 U of LA Taq DNA polymerase (TaKaRa), 1 mM of each of the forward (5 0 -CCAGAGCAGAGCAAACAGAAAAAAGTGGCTCCCCG-3'; 4015-4049, NM_005933) and reverse (5 0 -GGTTTCTTGAG-TCTTCTTCCCCCTCTTCACCCTGT-3'; 147 629-147 595, AC104687) primers and 500 ng of DNA extracted from cell line cells. After an initial denaturation for 1 min at 941C, 30 cycles of 20 s at 981C and 20 min at 681C were run, followed by a final extension for 10 min at 721C. For sequence analyses, the PCR-amplified fragments were run on 0.5% agarose gels, purified using a Qiagen gel extraction kit and directly sequenced.
Phylogenetic analysis of the human septin family
So far, 10 human septin genes (not including transcript variants) have been reported. The conserved GTP-binding domains of all 10 septins were used for alignment to create a phylogenetic tree by using ClustalW and Tree View.
Northern blot analysis
Multiple human-tissue Northern blots (Clontech, Palo Alto, CA, USA) were hybridized with a 32 P-labeled FLJ10849 cDNA probe. A 906-bp PCR product (nucleotides 322-1227, NM_018243) was used as a probe.
Results
Establishment of cell line
Peripheral blood mononuclear cells obtained from the patient were cultured as described in the Materials and methods. The cells were maintained without any feeder cells or growth factors. The first subculture was made 3 weeks after the culture was started. The cells proliferated consistently as free-floating suspensions. When established, the cell line was designated CNLBC1 (Figure 1b) . The cell line was grown continuously for more than 18 months. In one-step cell growth curve measurements, when initial cell densities were adjusted to 1 Â 10 5 cells/ ml, the maximum cell density of CNLBC1 was 2.4 Â 10 6 cells/ml with a doubling time of 36 h. The cells can be cryopreserved in defined medium (70% medium, 20% FCS, 10% DMSO), stored in liquid nitrogen, thawed again (with viabilities of more than 70%) and successfully reconstituted. The data presented here were obtained from cells that had been in culture for 4 months and did not change significantly during further culturing. The cell line is available through the first author upon written request.
Cell surface markers
The cell surface marker profile of the CNLBC1 cell line is summarized in Table 1 , along with comparable data for the fresh leukemia cells. The percentage of immunofluorescence-positive cells was calculated by immunofluorescence microscopy; mean values obtained from more than three tests are shown.
Cytogenetic analysis
The complete karyotype of stemline cells of CNLBC1 showed 49, XX, þ X, þ 8, þ 21, t(4;11)(q21;q23) (Figure 2a) , which was consistent with the original leukemia cell karyotype.
Rearrangement of MLL and noninvolvement of AF4
Southern blot analysis with an MLL probe of DNA prepared from the CNLBC1 cell line revealed chromosomal breakpoints within the breakpoint cluster region of the MLL gene (Figure 2b) . However, no PCR products were amplified from the cDNA prepared from these cells when the MLL-AF4-specific primer pair was used. We inferred that the MLL in this patient is fused to a novel partner gene.
Identification of the MLL fusion cDNA
After cloning and sequencing, we determined that six of 16 cDNA panhandle PCR products were wild-type MLL, but 10 were MLL exon 9 fused with unknown sequences that did not match the MLL gene or the partner genes of MLL that were cloned previously. A BLAST search showed that these remaining sequences were Homo sapiens hypothetical protein FLJ10849 (NM_018243). Sequence comparisons using the BLAST program indicated that nucleotide 4086 of MLL was fused in-frame with nucleotide 121 of FLJ10849 on 4q21 (Figure 3a) . We compared our cDNA and others with previously deposited genomic sequences in order to derive the genomic organization of FLJ10849. The accession number for the region containing the genomic sequence encompassing FLJ10849 is NT_016354. The positions of the exon-intron boundaries are given in the reference sequence NM_018243, and in total 10 exons were identified, ranging in size from 97 to 1478 bp: exon 1, nucleotides 1-120; exon 2, nucleotides 121-235; exon 3, nucleotides 236-431; exon 4, nucleotides 432-618; exon 5, nucleotides 619-780; exon 6, nucleotides 781-877; exon 7, nucleotides 878-1046; exon 8, nucleotides 1047-1179; exon 9, nucleotides 1180-1367; and exon 10, 1368-2845. Thus, cDNA A novel septin fuses MLL in t(4;11) leukemia K Kojima et al panhandle PCR revealed that the chimeric transcript had an inframe fusion of exon 9 of the MLL gene with exon 2 of the FLJ10849 gene.
Detection of MLL-FLJ10849 and reciprocal FLJ10849-MLL chimeric transcripts
RT-PCR analysis using primers MLL-3974F from MLL exon 8 and SEPT-304R from FLJ10849 exon 3 showed an expected 246-bp MLL-FLJ10849 fusion product in the CNLBC1 cell line. Nested RT-PCR, using outer primers SEPT-89F and MLL-4240R followed by inner primers SEPT-111F and MLL-4137R, showed a reciprocal FLJ10849-MLL chimeric transcript in which nucleotide 120 of FLJ10849 was fused in-frame with nucleotide 4087 of MLL (Figure 3b ). There was no mutation or deletion in the parts of the MLL and FLJ10849 genes included in their chimeric transcripts. These chimeric MLL-FLJ10849 and FLJ10849-MLL transcripts were detected in blastic phase cells but not in chronic phase cells. We could not detect any alternatively spliced FLJ10849 mRNAs in the MLL-FLJ10849 transcript.
Detection of genomic MLL-FLJ10849 hybrid
XL-PCR amplified a 5.7 genomic MLL-FLJ10849 fragment, partial sequencing of which showed that the breakpoints were located in intron 9 of MLL and intron 1 of FLJ10849 (Figure 4) . The genomic break in MLL occurred 1088 bp downstream of exon 9, 595 bp downstream of that found in the t(4;11)-positive (MLL-AF4-positive) cell line MV4-11. 33 The breakpoint in FLJ10849 was 5054 bp upstream of exon 2.
Identification of human FLJ10849
FLJ10849 encoded a putative 429 amino-acid protein beginning at nucleotide 94 with a predicted molecular mass of 49.4 kDa. The open-reading frame began at a methionine located within a strong Kozak context (RNNatgG) 34 and terminated at a stop codon downstream of which was located an AATAAA polyadenylation site. The FLJ10849 protein shares highest homology with human SEPT6, SEPT8 and SEPT10, with identity of 76-82% and similarity of 89-90% (Figure 5a ). To a lesser extent, it also A novel septin fuses MLL in t(4;11) leukemia K Kojima et al exhibited 40-44% identity and 58-65% similarity to other human septins. The FLJ10849 protein contains an N-terminal GTP-binding domain (GX4GKS-DX2G-KXD), which is highly conserved in the septin family, typically forms a flexible loop between a b-strand and an a-helix and is generally regarded to be crucial for their functions. Moreover, a coiled-coil domain is predicted to exist at its C-terminus. Human septin proteins were analyzed phylogenetically on the basis of their GTP-binding domains by using the ClustralW program. As shown in Figure 5b , FLJ10849 is most closely related to SEPT6, SEPT8 and SEPT10.
Expression of FLJ10849 gene in normal tissues
To examine the expression of FLJ10849, we performed Northern blot analysis on poly -A þ RNA from various human tissues and detected three types of transcripts, B2.0, 2.8 and 6.3 kb (Figure 6 ). The expression of these transcripts was detected in brain, heart, skeletal muscle, kidney and placenta. The weak expression was detectable in the spleen, liver, small intestine and lung. No obvious expression was observed in the colon, thymus and peripheral blood leukocyte.
Discussion
A t(4;11)(q21;q23) is a recurring chromosomal translocation observed in acute leukemias, and AF4 was previously cloned as a fusion partner of MLL. In the present study, we isolated a novel fusion partner of the MLL gene, FLJ10849, in a novel leukemia cell line CNLBC1 derived from CNL at blastic phase with t(4;11)(q21;q23). Recent molecular analysis has revealed the ABI-1 and AF10 genes in the same chromosomal region 10p11.2-12 and the ENL, ELL/MEN and EEN genes in 19p13.1-13.3 as fusion partners of MLL, 10, [35] [36] [37] [38] suggesting that molecular analysis is essential for the precise localization of the chromosomal translocations. The MLL-FLJ10849 fusion transcript was not detected in the leukemia cells in the chronic phase, indicating that the rearrangement occurred as a secondary genetic event along with blastic transformation and that the fusion per se is not associated with the pathogenesis of CNL. A recent critical review has described that cytogenetic abnormalities occur in 37% of cases of CNL and include trisomy 8, trisomy 21 and del(20q).
2 Trisomy 8 and trisomy 21 were also detected in our case at chronic phase. However, it remains unknown whether these two chromosome abnormalities are associated with the pathogenesis of CNL, because CNL is extremely rare and both abnormalities have been described in various hematological malignancies. [39] [40] [41] To clarify the genetic component that contributes to the development of CNL, not only is more cytogenetic data on large patient populations required but more detailed molecular studies must be carried out.
FLJ10849 is homologous with septin proteins. Septins are a family of nucleotide-binding proteins originally found in the yeast Saccharomyces cerevisiae as cell division cycle regulatory proteins. 42 The septin proteins are characterized by an evolutionarily conserved GTP-binding motif near the N-terminus, common to all septins, and by a coiled-coil domain at the C-terminus, with a few exceptions;
18,19 the putative FLJ10849 protein, which shares striking homology (76-82% identity and 89-90% similarity) with human septins SEPT6, SEPT8 and SEPT10, possesses both these domains. Furthermore, FLJ10849 was expressed almost ubiquitously in this study, being similar to many septins. Thus, we believe that FLJ10849 defines a novel septin family protein.
Three human septins, SEPT5, SEPT6 and SEPT9, have previously been identified as the fusion partners of MLL.
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The MLL-FLJ10849 fusion protein contains almost the entire septin protein as well as the NH 2 -terminus of MLL, including the DNA-binding regions, similar to MLL-SEPT5, MLL-SEPT6 and MLL-SEPT9. Therefore, a common region, for example, the GTPbinding domain, might be crucial for the leukemogenesis associated with MLL-septin fusion proteins. Similarly, the coiled-coil region, which is found in FLJ10849 as well as in SEPT5 and SEPT6, might also contribute to leukemogenesis. [20] [21] [22] [23] As for the reciprocal transcript, CNLBC1 also had an 'in-frame' FLJ10849-MLL fusion transcript. However, nested PCR was required for the detection, indicating that it is less expressed than MLL-FLJ10849 transcripts. Since both MLL-FLJ10849 and FLJ10849-MLL in-frame fusion transcripts were detected, it remains unknown whether MLL-FLJ10849, FLJ10849-MLL or both are leukemogenic. In previously reported MLL-septin leukemias, however, there have been no PCR-detectable septin-MLL fusion transcripts, 21, 23, 24 or even if present, the septin-MLL fusion transcript was 'out-of-frame'. 25 We therefore think that the MLL-septin transcript, but not the septin-MLL transcript, is critical to the leukemogenesis of MLL-septin leukemias. This view is supported by recent findings on the molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
6-8 MLL-septin fusion has been confined to AML. The identification of four septin family members as partner genes of MLL suggests an important common pathway to leukemogenesis in AML with these translocations.
The function of the MLL-septin fusion protein that could contribute to leukemogenesis remains unknown, although recent findings in yeast have revealed a connection between the regulation of mitosis and septins. [43] [44] [45] In budding yeast, septins can function in a morphogenetic checkpoint pathway by controlling the activity of the Nim1-related kinase Hsl1p, an upstream regulator of a kinase cascade that controls entry of cells into mitosis. Since the activity of Hsl1p depends on proper septin function, cytokinesis is delayed in septin mutants. Given that homologues of Nim1-related kinases are present in Figure 6 Northern blot analysis of FLJ10849 expression in normal human tissues. The RNA markers are indicated in kilobase (kb).
A novel septin fuses MLL in t(4;11) leukemia K Kojima et al mammals, an aberrant septin-dependent checkpoint control could disrupt mitosis and induce oncogenesis. Indeed, aberrant expression of septin family genes has been reported in some human cancers, including the brain, breast, colorectal and urologic cancers. [46] [47] [48] [49] In summary, we established a cell line from a patient with CNL, and demonstrated a novel fusion between the MLL gene and the FLJ10849 gene. Since there have been no CNL or MLLseptin leukemia cell lines available, CNLBC1 could serve as an excellent in vitro model for analyzing their leukemia pathogenesis.
